Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03891472
Other study ID # KNW/0022/KB1/71/I/16
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date January 1, 2017
Est. completion date July 31, 2019

Study information

Verified date November 2019
Source Medical University of Silesia
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Primary goal:

Improvement of the therapeutic index by reducing the toxicity of treatment and increasing local control of the cancer process while evaluating the possibility of conversion to the surgical status.

Secondary targets:

- Survival rate (OS) assessment in patients treated with mFOLFIRINOX + SBRT

- Assessment of quality of life using questionnaires: EQ-5D, EORTC (QLQ-C30) and pancreatic cancer-specific QLQ PAS module 26

- Early toxicity <3 months after completion of SBRT treatment.

- Percentage of local control (1-year)


Description:

STUDY PLAN Patients will receive initial mFOLFIRINOX (6 cycles) chemotherapy, followed by evaluation of the response to the treatment (imaging and laboratory testing) followed by SBRT, followed by mFOLFIRINOX chemotherapy.

In case of exclusion of disease progression after 10 weeks +/- 2 weeks after completion of SBRT, patients will be qualified to surgical treatment to attempt a radical surgical treatment.


Recruitment information / eligibility

Status Completed
Enrollment 40
Est. completion date July 31, 2019
Est. primary completion date July 31, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. Signing informed consent for treatment.

2. Age> = 18 years.

3. Patients with histopathological diagnosis of adenocarcinoma of the pancreas.

4. Advanced disease referred to as locally advanced definitive non-resetable, non-metastatic pancreatic cancer.

5. No prior systemic treatment due to pancreatic adenocarcinoma

6. No prior radiotherapy in the abdominal area

7. No prior radical surgical treatment due to pancreatic adenocarcinoma (palliative surgical procedures such as bypass surgery or biliary tract surgery are acceptable).

8. ECOG 0 or 1.

9. Expected survival time in excess of 12 weeks.

10. Adequate organ performance based on laboratory blood tests.

Exclusion Criteria:

1. Patients diagnosed with other types of pancreatic cancer than adenocarcinomas (eg neuroendocrine cancer).

2. Advanced disease that allows primary surgical treatment.

3. Borderline pancreatic cancer (BRPC) disease.

4. The presence of metastases.

5. Previous systemic treatment because of pancreatic adenocarcinoma.

6. Preoperative radiotherapy in the abdominal area.

7. Previous radical surgery for pancreatic adenocarcinoma.

8. Large surgical procedure with the exception of diagnostic biopsies within the last 4 weeks after the start of treatment and / or patients who have not fully recovered after surgery.

9. Heart failure (NYHA Class II, III or IV)

10. Hemodynamic instability in the course of coronary and / or valvular heart disease and / or hypertension and / or other clinical conditions (eg uncontrolled diabetes mellitus).

11. Clinically relevant cardiac arrhythmias requiring treatment.

12. Stroke and / or myocardial infarction history within 6 months of inclusion.

13. Respiratory failure associated with other co-morbidities.

14. Serious psychiatric illnesses, which, in the researcher's opinion, could have a significant negative impact on the safety of the treatment.

15. Other serious accompanying illnesses, which, in the researcher's opinion, could seriously adversely affect the safety of the treatment.

16. Transplanted organ transplant including allogeneic bone marrow transplant.

17. Positive diagnosis for HBV or HCV indicating acute or chronic infection (for screening).

18. HIV infection.

19. The period of pregnancy and breastfeeding.

20. Alcoholism or drug abuse.

21. Limited legal capacity.

Study Design


Intervention

Drug:
Patients will receive initial chemotherapy, followed by evaluation of the response to the treatment, followed by SBRT, followed by chemotherapy.
mFOLFIRINOX > SBRT > mFOLFIRINOX > Surgical Intervention

Locations

Country Name City State
Poland UCK Katowice Katowice Slaskie

Sponsors (1)

Lead Sponsor Collaborator
Medical University of Silesia

Country where clinical trial is conducted

Poland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Improvement of the therapeutic index. Improvement of the therapeutic index by reducing the toxicity of treatment and increasing local control of the cancer process while evaluating the possibility of conversion to the surgical status. 24 months.
Primary Improvement of the overall survival. Improvement of the overall survival by new treatment method. 60 months.
See also
  Status Clinical Trial Phase
Recruiting NCT06376604 - Fasting Mimicking Diet in Chemotherapy of Gynecologic Malignancies N/A
Completed NCT03753542 - Effect of Nurse-led Education on Parent's Anxiety and Depression on Managing Side Effects of Chemotherapy N/A
Not yet recruiting NCT05022628 - Clinical Study of Radiotherapy Combined With Donafenib for Neoadjuvant Treatment of Patients With HCC With Portal Vein Carcinoma Thrombosis Phase 4
Completed NCT04207359 - Effects of Creatine Supplementation in Breast Cancer Survivors N/A
Active, not recruiting NCT04489173 - TAS102 in Patients With ER-positive, HER2-negative Advanced Breast Cancer Phase 2
Completed NCT04173195 - Comfort Talk (CT) During Outpatient Chemotherapy N/A
Recruiting NCT06041477 - Concurrently vs Sequentially Combined HAIC With Targeted and Immunotherapy in Potentially Resectable HCC Phase 3
Recruiting NCT05014399 - Cognitive Impairment in Colorectal Cancer Patients Receiving Cytotoxic Chemotherapy
Recruiting NCT03275194 - HIPEC in Ovarian Carcinoma Clinical Stage IIIC and IV During Interval Laparotomy Phase 2
Recruiting NCT04808466 - Comparative Study of Lobaplatin and Paclitaxel in Advanced Gastric Cancer Patients With D2 Surgery Combined With Hyperthermic Intraperitoneal Chemotherapy Phase 2
Recruiting NCT06421610 - OPC5: Pressurized IntraThoracic Aerosol Chemotherapy (PITAC) in Patients With Malignant Pleural Effusion. Phase 1
Completed NCT05131490 - Effect on Adaptation to Cancer of Mobile Application Developed for Gynecological Cancer Patients N/A
Completed NCT04118322 - The Effect of Peppermint Oil on Nausea, Vomiting and Retching in Cancer Patients Undergoing Chemotherapy N/A
Recruiting NCT06043999 - Salvage Chemotherapy Versus Total Mesorectal Resection for Local Resection Rectal Cancer Patients N/A
Recruiting NCT05515796 - Multi-omics Sequencing in Neoadjuvant Immunotherapy of Gastrointestinal Tumors Phase 2
Not yet recruiting NCT04845490 - Comparative Study of Mitomycin and Lobaplatin in Advanced Colorectal Cancer Patients With Radical Surgery Combined With Hyperthermic Intraperitoneal Chemotherapy Phase 2
Recruiting NCT05992337 - New Biomarkers in the Prediction of Chemotherapy-induced Cardiotoxicity.
Recruiting NCT05424692 - Drug Sensitivity Detection of Micro Tumor (PTC) to Guide Postoperative Adjuvant Treatment Strategy of Colorectal Cancer N/A
Recruiting NCT04989985 - S-1 and Oxaliplatin (SOX) Plus Sintilimab in the Locally Advanced Esophagogastric Junction Adenocarcinoma Phase 2
Enrolling by invitation NCT04027478 - Can Fasting Decrease the Side Effects of Chemotherapy? N/A